Skip to main content
OpenTrials
Completed

NCT Number: NCT06460441

Comparison of the SUNRISE© Device With Ventilatory Polygraphy for the Diagnosis of Obstructive Sleep Apnea Hypopnea Syndrome: Collection of Preliminary Data

Additional data on screening for obstructive sleep apnea/hypopnea syndrome (OSAHS) in patients with co-morbidities, such as diabetics and those with chronic respiratory diseases would enable current recommendations to evolve, with a view to promoting the widespread use of simplified techniques for OSAHS screening, particularly in patients with cardiorespiratory co-morbidities.

The primary objective of this observational multicentric pilot study is to compare the performance of the Sunrise® medical device with that of ventilatory polygraphy as part of routine screening for OSAHS in diabetic patients followed up in the diabetology department of the Strasbourg University Hospital, and in patients followed up in the pneumology consultation department of Mulhouse Hospital (GHRMSA).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpitaux Universitaires de Strasbourg

Strasbourg, Bas-Rhin, France

About this study

Secondary objectives

  • To assess the correlation of the following parameters:
  • dorsal Apnea-Hypopnea Index (AHI) measured by ventilatory polygraphy and dorsal Obstructive Respiratory Disturbance Index (ORDI) measured by Sunrise® device
  • non-dorsal AHI measured by ventilatory polygraphy and non-dorsal ORDI measured by Sunrise® device
  • To study the correlation between AHI measured by the Sunrise® medical device and desaturation index measured by ventilatory polygraphy.

Conduct of research

  • At Strasbourg University Hospital, the study will be proposed to patients admitted for diabetic assessment who require ventilatory polygraphy.
  • At Mulhouse hospital (GHRMSA), patients are referred to a pneumologist in case of suspected OSAHS and a ventilatory polygraphy is scheduled at home. Patients scheduled to undergo this examination will be invited to take part in the study.

Ventilatory polygraphy (routine care):

Patients included in the study will receive an additional recording using the Sunrise© medical device, performed simultaneously with the ventilatory polygraphy.

Ventilatory polygraphy will be performed in accordance with each center's usual practices. For patients undergoing home polygraphy (GHRMSA), the care team will install the sensors and program the device for recording during sleep. The patient will return home and spend the night there, before coming back to the hospital the following day to give back the equipment. For patients hospitalized in the diabetology department of Strasbourg University Hospital, ventilatory polygraphy will be carried out during hospitalization.

Sunrise© medical device (examination added by research):

The mobile application will be installed on patient's smartphone by the study investigating team, and the use of the Sunrise© device will be explained to the patient. Recording will take place on the same night as the ventilatory polygraphy.

The day after recording, the Sunrise© sensor and ventilatory polygraph equipment will be collected by the investigating team.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged 18 or over;
  • Patient with a smartphone (Android or iOS) with Bluetooth and Internet connection and able to use the mobile application associated with the Sunrise© medical device;
  • Patient having a scheduled exploration by ventilatory polygraphy;
  • Non-opposition to participation in the research.

Exclusion criteria

  • Patient suffering from a psychiatric pathology or with a history of behavioral disorders;
  • Patient already treated for OSAHS;
  • Patient refusing to cut his beard (if too abundant to wear the Sunrise© device);
  • Patient suffering from a pathology affecting the rotation of the condyle in the temporomandibular joint;
  • Patient deprived of liberty by judicial or administrative decision;
  • Patients under court protection or legal guardianship.

Treatment and study plan

SUNRISE© device

Diagnostic Test

The device under study is the Sunrise© sensor, a single-use Class IIa medical device with CE marking and ISO 13485 certification.

The system combines a mandibular movement sensor with an artificial intelligence program to collect and interpret data. It consists of a three-gram device that is placed on the chin using an adhesive. The sensor is linked to a (free) mobile app, enabling data to be sent to the Sunrise© company's secured platform at the end of the night, and results to be transmitted to the prescribing physician.

Primary outcomes

  1. Apnea-hypopnea index (AHI)

    Time frame: Day 1

    The apnea-hypopnea index (AHI) will be measured using the Sunrise® medical device and ventilatory polygraphy. It corresponds to the number of apnea-hypopnea episodes per hour of sleep.

Secondary outcomes

  1. Dorsal AHI

    Time frame: Day 1

  2. Non- dorsal AHI

    Time frame: Day 1

  3. Dorsal Obstructive respiratory disturbance index (ORDI)

    Time frame: Day 1

  4. Non dorsal ORDI

    Time frame: Day 1

Sponsors and collaborators

Lead sponsor

Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

Other

Collaborators

  • University Hospital, Strasbourg, France

Registry information

Acronym: SUNPV

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jun 14, 2024
Registry last updated
May 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.